Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Gezira 12217, Sudan.
Department of Pharmaceutics, Faculty of Pharmacy, University of Gezira, Gezira 12217, Sudan.
Molecules. 2023 Mar 1;28(5):2289. doi: 10.3390/molecules28052289.
Non-Hodgkin's lymphomas are a diverse collection of lymphoproliferative cancers that are much less predictable than Hodgkin's lymphomas with a far greater tendency to metastasize to extranodal sites. A quarter of non-Hodgkin's lymphoma cases develop at extranodal sites and the majority of them involve nodal and extranodal sites. The most common subtypes include follicular lymphoma, chronic/small lymphocytic leukaemia, mantel cell lymphoma, and marginal zone lymphoma. Umbralisib is one of the latest PI3Kδ inhibitors in clinical trials for several hematologic cancer indications. In this study, new umbralisib analogues were designed and docked to the active site of PI3Kδ, the main target of the phosphoinositol-3-kinase/Akt/mammalian target of the rapamycin pathway (PI3K/AKT/mTOR). This study resulted in eleven candidates, with strong binding to PI3Kδ with a docking score between -7.66 and -8.42 Kcal/mol. The docking analysis of ligand-receptor interactions between umbralisib analogues bound to PI3K showed that their interactions were mainly controlled by hydrophobic interactions and, to a lesser extent, by hydrogen bonding. In addition, the MM-GBSA binding free energy was calculated. Analogue 306 showed the highest free energy of binding with -52.22 Kcal/mol. To identify the structural changes and the complexes' stability of proposed ligands, molecular dynamic simulation was used. Based on this research finding, the best-designed analogue, analogue 306, formed a stable ligand-protein complex. In addition, pharmacokinetics and toxicity analysis using the QikProp tool demonstrated that analogue 306 had good absorption, distribution, metabolism, and excretion properties. Additionally, it has a promising predicted profile in immune toxicity, carcinogenicity, and cytotoxicity. In addition, analogue 306 had stable interactions with gold nanoparticles that have been studied using density functional theory calculations. The best interaction with gold was observed at the oxygen atom number 5 with -29.42 Kcal/mol. Further in vitro and in vivo investigations are recommended to be carried out to verify the anticancer activity of this analogue.
非霍奇金淋巴瘤是一组多样化的淋巴增殖性癌症,其可预测性远低于霍奇金淋巴瘤,且更倾向于转移至结外部位。四分之一的非霍奇金淋巴瘤病例发生在结外部位,其中大多数涉及淋巴结和结外部位。最常见的亚型包括滤泡性淋巴瘤、慢性/小淋巴细胞白血病、套细胞淋巴瘤和边缘区淋巴瘤。Umbralisib 是几种血液系统癌症适应证临床试验中最新的 PI3Kδ 抑制剂之一。在这项研究中,设计了新的 Umbralisib 类似物,并对接至 PI3Kδ 的活性位点,即磷酸肌醇-3-激酶/Akt/雷帕霉素靶蛋白(PI3K/AKT/mTOR)途径的主要靶点。这项研究产生了 11 个候选物,它们与 PI3Kδ 的结合非常紧密,对接评分在-7.66 到-8.42 Kcal/mol 之间。对结合至 PI3K 的 Umbralisib 类似物的配体-受体相互作用的对接分析表明,它们的相互作用主要受疏水相互作用控制,在较小程度上受氢键控制。此外,还计算了 MM-GBSA 结合自由能。类似物 306 与 -52.22 Kcal/mol 的结合自由能最高。为了确定所提出配体的结构变化和复合物稳定性,使用了分子动力学模拟。基于这项研究结果,设计最佳的类似物 306 形成了稳定的配体-蛋白复合物。此外,使用 QikProp 工具进行的药代动力学和毒性分析表明,类似物 306 具有良好的吸收、分布、代谢和排泄特性。此外,它在免疫毒性、致癌性和细胞毒性方面具有有前景的预测特征。此外,类似物 306 与金纳米粒子的相互作用稳定,这一点已通过密度泛函理论计算得到验证。在氧原子编号为 5 时观察到与金的最佳相互作用,其相互作用能为-29.42 Kcal/mol。建议进一步进行体外和体内研究,以验证该类似物的抗癌活性。